Buildings and Landmarks Join LRF to Light Red and Raise Awareness for Blood Cancer Awareness Month
The tenth anniversary of the Lymphoma Research Foundation’s Blood Cancer Awareness Month initiative expected to reach millions.
Lymphoma News
Patient Perspectives: Using Consistent Terminology for Biomarker and Germline Genetic Testing
A multi-stakeholder working group recommends consistent biomarker, genetic and genomic testing terminology for patient education and clinical care.
U.S. Food and Drug Administration Approves Tafasitamab-cxix (MONJUVI) for Diffuse Large B-cell Lymphoma (DLBCL)
On July 31, 2020 the U.S. Food and Drug Administration (FDA) announced it has approved tafasitamab-cxix (MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic antibody, in combination with lenalidomide (REVLIMID) for adult patients with relapsed or refractory diffuse large B-cell lymphoma…
U.S. Food and Drug Administration Approves First CAR T Cell Therapy for Mantle Cell Lymphoma: Brexucabtagene Autoleucel (TECARTUS)
Brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company) has been approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). This is the first chimeric antigen receptor (CAR) T cell therapy approved for MCL.
U.S. Food and Drug Administration Approves Selinexor (XPOVIO) for Diffuse Large B-cell Lymphoma
Selinexor (XPOVIO, Karyopharm Therapeutics, Inc.) is a single-agent oral tablet approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma (FL), after at least 2 lines of systemic therapy.
U.S. Food and Drug Administration Approves Tazemetostat (TAZVERIK) and EZH2 Mutation Test for Follicular Lymphoma
Tazemetostat (TAZVERIK), an EZH2 inhibitor, and the EZH2 Mutation Test were granted approval for adult patients with relapsed or refractory follicular lymphoma (FL).
An Emerging Cancer: Survivors Advocate for Women’s Health and Awareness
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is impacting women globally—leaving many questions for both patients and providers.
U.S. Food and Drug Administration Approves Ibrutinib (IMBRUVICA) Plus Rituximab (RITUXAN) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This approval expands the use of acalabrutinib, which received accelerated approval from the FDA for the treatment of adult patients with mantle cell lymphoma (MCL).
Physical Activity and Exercise While Sheltering at Home
This article was contributed by Oncology Dietitian and Clinical Exercise Physiologist, Hannah Manella, MS, RD, LDN, ACSM-CEP, CET (Rush University Cancer Center). There is no doubt the coronavirus (COVID-19) pandemic and new stay-at-home mandates can make physical activity more challenging.…
Creating a Routine That’s Right for You During COVID-19
This article was contributed by mindfulness-based leadership coach and inspirational speaker, Amy Jin. Humans are creatures of habit, and routines can offer mental health benefits, as well as help you achieve your goals. For many of us, social distancing or…